Stock 000153 ANHUI FENGYUAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anhui Fengyuan Pharmaceutical Co., Ltd.

Equities

000153

CNE0000014X5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 17/06/2024 am IST 		5-day change 1st Jan Change
5.54 CNY -0.36% Intraday chart for Anhui Fengyuan Pharmaceutical Co., Ltd. -1.25% -17.23%
30/05 Anhui Fengyuan Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 07 June 2024 CI
23/05 Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,608 2,063 2,747 3,739 4,503 3,111
Enterprise Value (EV) 1 1,662 2,301 3,074 4,103 4,807 3,479
P/E ratio 26.8 x 25.5 x 26.5 x 32.6 x 27.8 x 19.5 x
Yield 1.94% - - 0.83% 0.74% 1.6%
Capitalization / Revenue 0.53 x 0.64 x 0.83 x 1.07 x 1.12 x 0.73 x
EV / Revenue 0.55 x 0.71 x 0.93 x 1.17 x 1.2 x 0.81 x
EV / EBITDA 9.37 x 12.7 x 15.9 x 18.5 x 18.2 x 11.8 x
EV / FCF 5.99 x 15.6 x -16.3 x -157 x 10.7 x -47.3 x
FCF Yield 16.7% 6.41% -6.13% -0.64% 9.37% -2.12%
Price to Book 1.27 x 1.56 x 1.94 x 2.45 x 2.61 x 1.65 x
Nbr of stocks (in thousands) 4,36,998 4,36,998 4,36,998 4,36,998 4,64,956 4,64,837
Reference price 2 3.679 4.721 6.286 8.557 9.686 6.693
Announcement Date 25/04/19 23/04/20 22/04/21 28/04/22 19/04/23 24/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,013 3,238 3,321 3,502 4,004 4,275
EBITDA 1 177.4 180.6 193 221.9 263.5 293.9
EBIT 1 102.9 110.4 122.7 145.6 170.5 193.6
Operating Margin 3.41% 3.41% 3.69% 4.16% 4.26% 4.53%
Earnings before Tax (EBT) 1 93.09 119.9 138.1 149.7 202.3 214.9
Net income 1 60.93 80.92 103.7 114.6 154.4 159.3
Net margin 2.02% 2.5% 3.12% 3.27% 3.86% 3.73%
EPS 2 0.1372 0.1849 0.2374 0.2622 0.3478 0.3426
Free Cash Flow 1 277.6 147.4 -188.4 -26.15 450.6 -73.61
FCF margin 9.21% 4.55% -5.67% -0.75% 11.25% -1.72%
FCF Conversion (EBITDA) 156.44% 81.65% - - 171.01% -
FCF Conversion (Net income) 455.56% 182.18% - - 291.8% -
Dividend per Share 2 0.0714 - - 0.0714 0.0714 0.1071
Announcement Date 25/04/19 23/04/20 22/04/21 28/04/22 19/04/23 24/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 54.6 237 327 364 304 368
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.3078 x 1.314 x 1.696 x 1.639 x 1.152 x 1.251 x
Free Cash Flow 1 278 147 -188 -26.1 451 -73.6
ROE (net income / shareholders' equity) 4.83% 6.16% 7.36% 7.28% 8.56% 8.56%
ROA (Net income/ Total Assets) 2.23% 2.1% 2.13% 2.44% 2.5% 2.73%
Assets 1 2,736 3,852 4,866 4,694 6,181 5,832
Book Value Per Share 2 2.900 3.030 3.230 3.500 3.720 4.060
Cash Flow per Share 2 0.6800 0.8000 0.6300 0.5800 0.7600 0.6900
Capex 1 84.6 146 191 157 81.8 152
Capex / Sales 2.81% 4.5% 5.74% 4.49% 2.04% 3.56%
Announcement Date 25/04/19 23/04/20 22/04/21 28/04/22 19/04/23 24/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. Stock Anhui Fengyuan Pharmaceutical Co., Ltd.
-17.23% 35Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.82% 80TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.68% 63TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.88% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.95% 32TCr
ABBVIE INC. Stock AbbVie Inc.
+9.49% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
+0.90% 22TCr
AMGEN INC. Stock Amgen Inc.
+5.30% 16TCr
PFIZER, INC. Stock Pfizer, Inc.
-6.29% 15TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000153 Stock
  4. Financials Anhui Fengyuan Pharmaceutical Co., Ltd.